InMed Pharmaceuticals (INM) Profit After Tax (2019 - 2026)

InMed Pharmaceuticals' Profit After Tax history runs 8 years deep, the most recent figure standing at -$3.0 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 39.86% year-over-year to -$3.0 million in Q1 2026; TTM through Mar 2026 was -$8.5 million, a 1.76% decrease from a year earlier, with the FY2025 full-year figure at -$8.2 million, down 6.49% from the prior year.
• Profit After Tax slipped to -$3.0 million in Q1 2026 per INM's latest filing, from -$2.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$300000.0 in Q2 2023 and bottomed at -$7.9 million in Q2 2022.
• The 5-year median for Profit After Tax is -$2.0 million (2025), against an average of -$2.5 million.
• Across the five-year window, Profit After Tax soared 96.19% in 2023 and tumbled 566.67% in 2024, its largest moves.
• Year by year, Profit After Tax stood at -$2.1 million in 2022, then grew by 29.65% to -$1.5 million in 2023, then sank by 74.2% to -$2.6 million in 2024, then climbed by 21.23% to -$2.0 million in 2025, then sank by 46.25% to -$3.0 million in 2026.
• Per Business Quant, the three latest INM Profit After Tax figures stand at -$3.0 million (Q1 2026), -$2.0 million (Q4 2025), and -$1.7 million (Q3 2025).